四环医药(00460.HK)收购北京康明百奥新药研发有限公司
四环医药(00460.HK)公布,已签订框架协议以收购北京康明百奥新药研发有限公司。收购完成後,公司将会成为康明百奥的拥有人。
公司指,康明百奥的业务聚焦於大分子药物的开发,拥有海内外的自主研发团队,拥有实力强大的自主研发技术平台,可以同时开展双抗和ADC的药物研究与开发。其中,Her2靶点的双抗及双抗ADC药物能够与集团已有的乳腺癌等药物进行联合开发,为集团旗下附属公司的创新研发带来强大的生物医药研发管线,同时为集团目前拥有的小分子创新药研发平台带来很好的研发能力和产品管线的补充。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.